Clinical trial · Interventional
Benzydamine vs Supersaturated Calcium Phosphate Oral Rinses for Radiation Induced Oral Mucositis in Head and Neck Cancer Patients.
COMPARISON Between TWO MOUTHWASHES in the Prevention and Management of ORAL MUCOSITIS During RADIOTHERAPY of HEAD AND NECK CANCER Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to compare and correlate salivary macrophage migratory inhibitory factor levels with onset and severity of radiation induced mucositis in head and neck cancer patients by using super saturated calcium phosphate solution and benzydamine hydrochloride oral rinses. Participants are patients of head and neck cancers undergoing radiation therapy of either gender. participants are divided into two groups Group A: Benzydamine group Group B: Super saturated calcium phosphate group * Participants will be using Oral rinses of their respective group and will be assessed for radiation induced oral mucositis at weekly intervals during radiation treatment. * salivary Macrophage migratory inhibitory factor levels will be assessed through ELISA, before and after the radiation treatment as per protocol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiation Induced Oral Mucositis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Benzydamine hydrochloride mouthrinse | Drug | — | UNRESOLVED |
| Super saturated calcium phosphate oral rinses | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group A Benzydamine group
- description
- group A will use benzydamine oral rinses throughout their radiation treatment
- interventionNames
- Drug: Benzydamine hydrochloride mouthrinse
- type
- EXPERIMENTAL
- label
- Group B super saturated calcium phosphate group
- description
- group B will use super saturated calcium phosphate oral rinses throughout their radiation treatment
- interventionNames
- Drug: Super saturated calcium phosphate oral rinses
Primary outcomes (2)
- measure
- Salivary macrophage migratory inhibitory Levels
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of either gender (age group 30-70 years) with any histological type of head and neck cancers having a treatment plan to receive radiotherapy. Exclusion Criteria: * Patients with poorly controlled diabetes mellitus * Patients with prior xerostomia * Patients with a history of chemo/radiotherapy
References
Publications (0)
Data not yet available